Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer

Surgery Today 2026

View at publisher
Authors: Michinori Matsumoto, Shinji Itoh, Masashi Tsunematsu, Kyohei Yugawa, Kenei Furukawa, Koichiro Haruki, Yoshihiro Shirai, Tomohiko Taniai, Mitsuru Yanagaki, Ryoga Hamura, Tadashi Uwagawa, Norimitsu Okui
+4 more Yoshiaki Tanji, Munetoshi Akaoka, Tomoharu Yoshizumi, Toru Ikegami
DOI: 10.1007/s00595-025-03227-3
Cited by: 0
References: 32

Fields of Study & Subjects

Cholangiocarcinoma and Gallbladder Cancer Studies Thyroid Cancer Diagnosis and Treatment Liver Diseases and Immunity

Publication details

Journal / source
Surgery Today
Volume
56
Issue
7
Pages
1158–1168
Publication date
5 January 2026
Language
EN